ANDA 77584, held by Zydus Pharmaceuticals (USA). Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 77584 (Paroxetine Hydrochloride), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Mar 7, 2007, with 19 approved supplements and 0 published complete response letters.
Paroxetine tablets are indicated in adults for the treatment of: Major depressive disorder (MDD) Obsessive compulsive disorder (OCD) Panic disorder (PD) Social anxiety disorder (SAD) Generalized anxiety disorder (GAD) Posttraumatic stress disorder (PTSD) Paroxetine is a selective serotonin reuptake inhibitor (SSRI) indicated in adults for the treatment of: Major Depressive Disorder (MDD) Obsessive Compulsive Disorder (OCD) Panic Disorder (PD) Social Anxiety Disorder (SAD) Generalized Anxiety Disorder (GAD) Posttraumatic Stress Disorder (PTSD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 7, 2007 | Original application | Approved | None posted |
| Paroxetine HydrochlorideEQ 10MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 20MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 30MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 40MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Feb 28, 2025 | Supplement 38Labeling · Standard review | Approved | None posted |
| Jun 12, 2024 | Supplement 37Labeling · Standard review | Approved | None posted |
| Feb 25, 2022 | Supplement 35Labeling · Standard review | Approved | None posted |
| Feb 25, 2022 | Supplement 34Labeling · Standard review | Approved | None posted |
| Mar 19, 2020 | Supplement 29Labeling · Standard review | Approved | None posted |
| Mar 19, 2020 | Supplement 28Labeling · Standard review | Approved | None posted |
| Jan 19, 2015 | Supplement 27Labeling · Standard review | Approved | None posted |
| Nov 26, 2014 | Supplement 23Manufacturing | Approved | None posted |
| Aug 19, 2013 | Supplement 25Labeling · Standard review | Approved | None posted |
| Aug 19, 2013 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jul 31, 2012 | Supplement 19Labeling | Approved | None posted |
| Jul 27, 2011 | Supplement 18Labeling | Approved | None posted |
| Mar 4, 2011 | Supplement 17Labeling | Approved | None posted |
| Jan 30, 2011 | Supplement 13Manufacturing | Approved | None posted |
| Oct 15, 2010 | Supplement 15Labeling | Approved | None posted |
| Apr 29, 2009 | Supplement 10Labeling | Approved | None posted |
| Apr 29, 2009 | Supplement 9Labeling | Approved | None posted |
| May 29, 2008 | Supplement 7Labeling | Approved | None posted |
| May 20, 2008 | Supplement 2Labeling | Approved | None posted |
| Mar 7, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters